Table 1

Volume 26, Number 7—July 2020

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M.A. Okba¹, Marcel A. Müller¹, Wentao Li¹, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B.E.M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, and Bart L. Haagmans

Author affiliations: Erasmus Medical Center, Rotterdam, the Netherlands (N.M.A. Okba, C.H. GeurtsvanKessel, M.M. Lamers, R.S. Sikkema, E. deBruin, F.D. Chandler, C.B.E.M. Reusken, M.P.G. Koopmans, B.L. Haagmans); Charité-Universitätsmedizin Berlin, Berlin, Germany (M.A. Müller, V.M. Corman, C. Drosten); German Centre for Infection Research, Berlin (M.A. Müller, V.M. Corman, C. Drosten); Utrecht University, Utrecht, the Netherlands (W. Li, C. Wang, B.-J. Bosch); Université de Paris, Paris, France (Y. Yazdanpanah, Q. Le Hingrat, D. Descamps); Hôpital Bichat-Claude Bernard, Paris (Y. Yazdanpanah, Q. Le Hingrat, D. Descamps, N. Houhou-Fidouh); RIVM, Bilthoven, the Netherlands (C.B.E.M. Reusken)

Main Article

Cohorts used to validate specificity and sensitivity of assays for SARS-CoV-2*

Cohort	Country	Sample source	Infection	No. samples	Postdiagnosis range or time
A	The Netherlands	Healthy blood donors (negative cohort)	NA	45	NA
B	The Netherlands	Non-CoV respiratory infections†	Adenovirus	5	2–4 wk
			Bocavirus	2	2–4 wk
			Enterovirus	2	2–4 wk
			HMPV	9	2–4 wk
			Influenza A	13	2–4 wk
			Influenza B	6	2–4 wk
			Rhinovirus	9	2–4 wk
			RSV	9	2–4 wk
			PIV-1	4	2–4 wk
			PIV-3	4	2–4 wk
			Mycoplasma pneumoniae	1	2–4 wk
			CMV	5	2–4 wk
			EBV	7	2–4 wk
C	The Netherlands	HCoV infections†	α-CoV HCoV-229E	19	2 w–1 y
			α-CoV HCoV-NL63	18	2 w–1 y
			β-CoV HCoV-OC43	38	2 w–1 y
D	The Netherlands	Zoonotic CoV infections†	MERS-CoV	2	10,228 d
D	South Korea		MERS-CoV	5	9 mo
E	Hong Kong, China	Zoonotic CoV infection†	SARS-CoV	2	>14 d
F	France	RT-PCR confirmed SARS-CoV-2 infections	Mild infection	6‡	3–27 d
F	France	RT-PCR confirmed SARS-CoV-2 infections	Severe infection	4§	6–31 d

*Cohorts A–E were used to test assay specificity; cohort F was used to test assay sensitivity. α-CoV, alphacoronavirus; β-CoV, betacoronavirus; CoV, coronavirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HCoV, human coronavirus; HMPV, human metapneumovirus; MERS, Middle East respiratory syndrome; NA, not applicable; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RT-PCR, reverse transcription PCR.
†Cross-reactivity.
‡Samples taken from 2 patients at different time points.
§Samples taken from 1 patient at different time points.

Main Article

¹These authors contributed equally to this article.

Page created: April 08, 2020

Page updated: June 18, 2020

Page reviewed: June 18, 2020

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.